
Quick Links
You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
*本文来源于《医药代表》公众号对安斯泰来大中华商业总经理滨口洋先生的独家专访,全文如下:...
- Enfortumab vedotin是日本首个也是唯一一个获准用于治疗患有晚期尿路上皮癌患者的抗体偶联药物(ADC) 2021年9月27日,东京和华盛顿州波士尔市 -...
Read more about 日本厚生劳动省批准将PADCEV®(enfortumab vedotin)用于治疗晚期尿路上皮癌
安斯泰来在研的非激素类疗法可降低绝经相关中至重度血管舒缩症状(VMS)的发生频率和严重程度 2021年9月22日,东京 -安斯泰来制药集团...
Read more about 安斯泰来在北美绝经学会2021年年会的口头报告中发表3期SKYLIGHT 2TM临床试验的12周结果
安斯泰来与辉瑞联合开发的XTANDI®(通用名恩扎卢胺)在3期ARCHES临床试验中可将男性转移性激素敏感性前列腺癌的死亡风险降低34%...
Read more about XTANDI®(通用名恩扎卢胺)在3期ARCHES临床试验中可将男性转移性激素敏感性前列腺癌的死亡风险降低34%
-基于验证性EV-301试验总生存期结果的常规批准...
Read more about 美国FDA授予PADCEV® (enfortumab vedotin-ejfv)常规批准及扩展适应症:用于治疗局部晚期或转移性尿路上皮癌患者
